CRPOF News and Press, Ceapro Inc From 04/20/21

The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...

– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes – – New PGX-based products developed under the colla...

EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and c...

We are trying something new this year where we share and track the 2021 Top Ideas from our Marketplace contributors. We start off with our Tech/Growth and Value stock contributors and highlight two picks that quickly peaked with 70% returns in under two weeks. Next week, we'll sha...

EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthca...

EDMONTON, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...

EDMONTON, Alberta, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO ; OTCQX: CRPOF ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for he...

EDMONTON, Alberta, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet...

– Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history – – R&D activities focused on the development of innovative delivery systems ...

– First milestone successfully achieved in early stages of the ongoing research project with McMaster University – Confirmed capability of PGX Technology to optimize and standardize the size and morphology of yeast beta-glucan (PGX-YBG) suitable for lung inhalation ...